Neuren Pharmaceuticals
NEU.AX
#5561
Rank
NZ$1.61 B
Marketcap
$12.59
Share price
0.87%
Change (1 day)
-40.29%
Change (1 year)

P/E ratio for Neuren Pharmaceuticals (NEU.AX)

P/E ratio at the end of 2023: 19.0

According to Neuren Pharmaceuticals's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 8.75132. At the end of 2023 the company had a P/E ratio of 19.0.

P/E ratio history for Neuren Pharmaceuticals from 2005 to 2023

PE ratio at the end of each year

Year P/E ratio Change
202319.0-99.62%
2022> 1000-9881.16%
2021-51.0305.04%
2020-12.6-40.3%
2019-21.1-147%
201844.9-132.48%
2017-1381776.77%
2016-7.36-41.75%
2015-12.6-25.57%
2014-17.089.19%
2013-8.9878.92%
2012-5.0281.44%
2011-2.77248.05%
2010-0.7945-101.24%
200964.2-47387.89%
2008-0.1357-90.93%
2007-1.50-58.92%
2006-3.64-34.95%
2005-5.60

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.